financetom
Business
financetom
/
Business
/
Recursion Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Trial of REC-1245 in Solid Tumors, Lymphoma
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Recursion Pharmaceuticals Gets US FDA Clearance for Phase 1/2 Trial of REC-1245 in Solid Tumors, Lymphoma
Oct 2, 2024 11:00 PM

08:46 AM EDT, 10/02/2024 (MT Newswires) -- Recursion Pharmaceuticals ( RXRX ) said Wednesday that the US Food and Drug Administration cleared the company's investigational new drug application for a phase 1/2 trial of REC-1245 as treatment for solid tumors and lymphoma.

The trial, which is scheduled to begin in Q4, will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and potential monotherapy efficacy of REC-1245, the company said.

Price: 6.20, Change: +0.03, Percent Change: +0.49

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Viridian Therapeutics Submits Biologics License Application for Thyroid Eye Disease Therapy
Viridian Therapeutics Submits Biologics License Application for Thyroid Eye Disease Therapy
Nov 3, 2025
10:30 AM EST, 11/03/2025 (MT Newswires) -- Viridian Therapeutics ( VRDN ) submitted a Biologics License Application to the U.S. Food and Drug Administration in October for veligrotug, its investigational therapy for the treatment of thyroid eye disease. Veligrotug has demonstrated promising results in pivotal clinical studies, with data showing improvement in proptosis, diplopia, and other key measures of disease...
Willis Lease Finance's JV Secures $750 Million Revolving Credit Facility
Willis Lease Finance's JV Secures $750 Million Revolving Credit Facility
Nov 3, 2025
10:30 AM EST, 11/03/2025 (MT Newswires) -- Willis Lease Finance ( WLFC ) said Monday its joint venture Willis Mitsui & Co. Engine Support has entered into a new $750 million five-year revolving credit facility. The facility will be available on a revolving basis until Oct. 31, 2030, and may be extended with lender approval, the company said. Loans will...
SM Energy, Civitas Resources to Merge in All-Stock Deal
SM Energy, Civitas Resources to Merge in All-Stock Deal
Nov 3, 2025
10:29 AM EST, 11/03/2025 (MT Newswires) -- SM Energy ( SM ) and Civitas Resources ( CIVI ) agreed to merge in an all-stock deal, creating one of the largest independent oil-focused producer operating across US shale basins. Shareholders of Civitas will receive 1.45 shares of SM Energy ( SM ), valuing the combined entity at about $12.8 billion, including...
LTC Properties Acquires Senior Housing Community for $23 Million
LTC Properties Acquires Senior Housing Community for $23 Million
Nov 3, 2025
10:34 AM EST, 11/03/2025 (MT Newswires) -- LTC Properties ( LTC ) said Monday it acquired a senior housing operating portfolio, or SHOP, in Georgia for $23 million. The 88-unit community currently has a 90% occupancy rate and is expected to deliver a year-one yield of around 7%, the company said. The real estate investment trust plans to complete an...
Copyright 2023-2026 - www.financetom.com All Rights Reserved